Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Operations: 2009-2024

Historic Cash from Operations for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to -$353.0 million.

  • Iovance Biotherapeutics' Cash from Operations fell 33.45% to -$78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$323.2 million, marking a year-over-year increase of 11.13%. This contributed to the annual value of -$353.0 million for FY2024, which is 2.44% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cash from Operations stood at -$353.0 million for FY2024, which was up 2.44% from -$361.8 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Cash from Operations peaked at -$205.1 million during FY2020, and registered a low of -$361.8 million during FY2023.
  • In the last 3 years, Iovance Biotherapeutics' Cash from Operations had a median value of -$353.0 million in 2024 and averaged -$335.9 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Cash from Operations fell by 29.11% in 2020, and later climbed by 2.44% in 2024.
  • Over the past 5 years, Iovance Biotherapeutics' Cash from Operations (Yearly) stood at -$205.1 million in 2020, then declined by 11.12% to -$227.9 million in 2021, then decreased by 28.44% to -$292.8 million in 2022, then decreased by 23.59% to -$361.8 million in 2023, then increased by 2.44% to -$353.0 million in 2024.